Slide 1: Q3 2016 Results Presentation
Q3 2016 Results Presentation Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, October 6, 2016
Slide 2: Disclaimer
Disclaimer 1. This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Business Review Q3 2016
Business Review Q3 2016 Uwe Röhrhoff, CEO
Slide 4: Disposal of Life Science Research for an enterprise value of USD 131m
Disposal of Life Science Research for an enterprise value of USD 131m to further focus on our core business Kimble Chase, the joint venture (51/49%) between Gerresheimer and Chase Scientific Glass, Inc., is to be sold to Duran Group, a portfolio company of One Equity Partners Total enterprise value
Slide 5: Review Q3 2016: again excellent earnings with an adjusted EPS increase by 40 percent
Review Q3 2016: again excellent earnings with an adjusted EPS increase by 40 percent Key Group figures in EUR m, adj. EPS in EUR Revenues Adjusted EBITDA Organic FXN: +1.4% Q3 2016 FXN: EUR 81.2m +8.4% +24.2% 373.1 84.4 344.0 68.0 22.6% Margin 19.8% Category Q3 2015 Q31 2016 Category Q3 2015 Q31 201
Slide 6: Financial Overview Q3 2016
Financial Overview Q3 2016 Rainer Beaujean, CFO
Slide 7: Q3 2016 revenues show 8.4% growth driven by Plastics & Devices
Q3 2016 revenues show 8.4% growth driven by Plastics & Devices Revenues by division Q3 2016 Q3 2015 Growth EUR m EUR m in % Total Group 373.1 344.0 +8.4 Plastics & Devices 195.2 153.1 +27.5 Primary Packaging Glass 155.2 170.5 -8.9 Life Science Research 24.1 25.8 -6.5 7
Slide 8: Adjusted EBITDA in Q3 2016: excellent earnings performance driven by Centor and productivity improvements
Adjusted EBITDA in Q3 2016: excellent earnings performance driven by Centor and productivity improvements Adjusted EBITDA1 by division Q3 2016 Q3 2015 EUR m Margin in % EUR m Margin in % Total Group 84.4 22.6 68.0 19.8 Plastics & Devices 54.4 27.9 31.6 20.6 Primary Packaging Glass 32.0 20.6 38.4 22.
Slide 9: Q3 2016 shows strong improvements in EBIT and net income
Q3 2016 shows strong improvements in EBIT and net income in EUR m Q3 2016 Q3 2015 Change in % Adjusted EBITDA 84.4 68.0 +24.2 Depreciation -22.0 -19.8 - Adjusted EBITA 62.4 48.2 +29.3 Total one-off effects -0.9 -8.4 - Amortization of fair value adjustments -9.5 -3.6 - Result from operations (EBIT) 5
Slide 10: Q3 2016: 40% increase in adjusted EPS
Q3 2016: 40% increase in adjusted EPS Reconciliation from net income to adjusted EPS in EUR m Q3 2016 Q3 2015 Change in % Net income 32.0 20.2 +58.7 Total one-off effects (net of related tax effects) +0.4 +6.4 - Amortization of fair value adjustments (net of related tax effect) +6.3 +2.6 - Adjusted
Slide 11: Net financial debt slightly improved
Net financial debt slightly improved Comparison of debt/cash positions in EUR m Net financial debt: 871.2 900.0 Bonded loans (Schuldschein): fixed/variable interest rates, 425.0 425.0 currently between ~1% and ~2%; (maturity in 2020, 2022 and 2025) Bond: Fixed annual coupon of 300.0 300.0 5.0% (matu
Slide 12: Average NWC in % of LTM revenues on our target level of 17%
Average NWC in % of LTM revenues on our target level of 17% Aug 31, 2016 May 31, 2016 Change in % EUR m EUR m Total assets 2,398.9 2,359.4 +1.7 Equity 725.1 687.8 +5.4 Equity ratio 30.2% 29.2% - Net working capital1 243.7 230.7 +5.6 16.7% 16.1% - NWC in % of LTM revenues average NWC in % of 16.6% 17
Slide 13: Guidance FY 2016
Guidance FY 2016 Uwe Röhrhoff, CEO
Slide 14: Adjustment of Guidance FY 2016 as a consequence of Life Science Research divestment
Adjustment of Guidance FY 2016 as a consequence of Life Science Research divestment Life Science Research divestment has to be reported as discontinued operation according to IFRS 5 All income and expense positions are retroactively adjusted for FY 2015 and FY 2016 and reported as net income from di
Slide 15: Adjusted Guidance for FY 2016 due to the classification of the segment LSR as discontinued operation
Adjusted Guidance for FY 2016 due to the classification of the segment LSR as discontinued operation Guidance FY 2016 Indication FY 2016-2018 Revenues (FXN)1 Approx. EUR 1.4bn (plus/minus EUR 25m) FXN growth1,2 Approx. +10% +4% to +5% CAGR (organic) Organic growth1,3 Approx. +4% to +5% Adjusted EBIT
Slide 16: Key takeaways
Key takeaways We have stable and highly diversified growth prospects based on long-term megatrends Profitability significantly improved – Q3 2016 figures make this visible once again The disposal of our Life Science Research division as a consequent step to strengthen our core business We focus on d
Slide 17: Q&A Session
we. GERRESHEIMER | . -_-* ~% Q&A Session
Slide 18: Backup
rt mee. GERRESHEIMER ame : - i le = |, \ NZ Backup
Slide 19: Favorable development of net working capital
Favorable development of net working capital1 Aug 31, 2016 Aug 31, 2015 EUR m EUR m Inventories 188.0 202.5 thereof prepayments made 4.6 6.5 Trade receivables 238.4 202.1 Trade payables 136.3 114.6 Payments received on account 46.4 35.7 of orders Net working capital 243.7 254.3 in % of LTM revenues
Slide 20: GXI Key Data
GXI Key Data in EUR per share 2008 2009 2010 2011 2012 2013 2014 2015 EPS 0.02 0.18 1.38 1.61 1.98 1.98 2.11 3.32 Adjusted EPS 1.83 1.34 1.95 2.44 2.62 3.08 2.89 3.41 Cash flow from operations per share 5.26 3.74 5.09 4.13 5.53 4.67 5.04 6.49 Dividend 0.40 --- 0.50 0.60 0.65 0.70 0.75 0.85 Dividend
Slide 21: Financial calendar and contact details
Financial calendar and contact details February 15, 2017 Annual Report Financial Year 2016 April 6, 2017 Interim Report 1st Quarter 2017 April 26, 2017 Annual General Meeting 2017 July 13, 2017 Interim Report 2nd Quarter 2017 October 11, 2017 Interim Report 3rd Quarter 2017 Name Investor Relations P